Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

Clinical trial NCT00825487 · COMPLETED

Trial details

NCT number: NCT00825487
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies

Start date: 2009-08-01
Primary completion: 2011-05-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.